Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors von Middleton, M.R., Azaro, A., Kumar, S., Niedermann, P., Rodón, J., Herbschleb, K.H., Steiner, J., Zitt, C., Feurstein, D., Schreiner, S., Turner, D., Dawson, K., Tadjalli-Mehr, K., Baur, Evom, Stumpp, M., Harstrick, A., Baird, R., Omlin, A.

Volltext